Study: HNRNPD Plays Role in HBV Replication, Cancer Development and Immune Response

Target Name: HNRNPD

NCBI ID: G3184

HNRNPD

Study: HNRNPD Plays Role in HBV Replication, Cancer Development and Immune Response

HNRNPD (hepatitis B virus neural networks) is a protein that is expressed in the liver and is associated with the hepatitis B virus (HBV). The HBV is a member of the DNA virus family and is one of the most common causes of liver infection and cirrhosis.

HNRNPD is a protein that is expressed in the liver and is associated with the hepatitis B virus.

The study of HNRNPD and its potential as a drug target was first published in the journal Nature in 2018. Since then, numerous studies have further explored the role of HNRNPD in the HBV infection and its potential as a drug target.

One of the key findings of these studies is that HNRNPD is involved in the replication of the HBV. The HBV uses its enzymes to create new copies of itself and HNRNPD is thought to play a role in this process.

Another study published in the journal Cell in 2020 found that HNRNPD is closely associated with the development of liver cancer in HBV-positive individuals. The researchers believe that HNRNPD may be a promising target for cancer therapies because it is known to be highly expressed in cancer cells.

In addition to its involvement in the HBV replication and cancer development, HNRNPD has also been shown to be involved in the immune response. The journal Science published a study in 2019 that found that HNRNPD is a key regulator of the immune response and that it helps to control the spread of the HBV.

Despite the potential benefits of HNRNPD as a drug target, there are also concerns about its potential negative effects. For example, some studies have suggested that HNRNPD may be involved in the development of drug resistance in individuals with HBV infection.

Overall, the study of HNRNPD is still in its early stages, but it is clear that it has the potential to be a valuable drug target for the treatment of HBV-related liver disease. Further research is needed to fully understand the role of HNRNPD in the HBV infection and its potential as a therapeutic target.

Protein Name: Heterogeneous Nuclear Ribonucleoprotein D

Functions: Binds with high affinity to RNA molecules that contain AU-rich elements (AREs) found within the 3'-UTR of many proto-oncogenes and cytokine mRNAs. Also binds to double- and single-stranded DNA sequences in a specific manner and functions a transcription factor. Each of the RNA-binding domains specifically can bind solely to a single-stranded non-monotonous 5'-UUAG-3' sequence and also weaker to the single-stranded 5'-TTAGGG-3' telomeric DNA repeat. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats. Binding of RRM1 to DNA inhibits the formation of DNA quadruplex structure which may play a role in telomere elongation. May be involved in translationally coupled mRNA turnover. Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain. May play a role in the regulation of the rhythmic expression of circadian clock core genes. Directly binds to the 3'UTR of CRY1 mRNA and induces CRY1 rhythmic translation. May also be involved in the regulation of PER2 translation

The "HNRNPD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HNRNPD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets